Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.20, Briefing.com reports. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The business’s revenue was up 46.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.47) EPS.

Agios Pharmaceuticals Trading Down 0.1 %

Shares of AGIO opened at $34.54 on Monday. The firm has a market cap of $1.96 billion, a PE ratio of -5.47 and a beta of 0.81. The firm has a fifty day simple moving average of $30.61 and a two-hundred day simple moving average of $25.68. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $35.50.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AGIO. JPMorgan Chase & Co. dropped their price target on Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating on the stock in a research report on Friday, February 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Tuesday, April 9th. Royal Bank of Canada decreased their price objective on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Finally, The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $29.00 to $33.00 and gave the stock a “neutral” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.00.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 4,156 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now directly owns 53,780 shares in the company, valued at approximately $1,751,614.60. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, insider James William Burns sold 2,642 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares of the company’s stock, valued at approximately $1,124,251.26. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Brian Goff sold 4,156 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the sale, the chief executive officer now directly owns 53,780 shares of the company’s stock, valued at approximately $1,751,614.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,035 shares of company stock worth $475,277. Insiders own 4.24% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.